Interaction between glycosaminoglycans and immunoglobulin light chains

Area of Science:

• Biochemistry
• Molecular Biology
• Pathology

Background:

• Amyloidosis involves protein polymerization into insoluble fibrils, implicated in diseases like Alzheimer's.
• Current treatments for amyloidosis are limited due to a poor understanding of its biophysical basis.
• Glycosaminoglycans (GAGs) are known to associate with amyloid fibrils.

Purpose of the Study:

• To investigate the interaction between amyloid-associated free light chains and GAGs.
• To explore the potential of GAGs as a basis for novel amyloidosis antagonists.

Main Methods:

• Size-exclusion high-performance liquid chromatography.
• Sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
• Molecular modeling of GAG-protein interactions.

Main Results:

• Heparin and chondroitin sulfates precipitated human intact light chains and recombinant light chain variable domains.
• Strongest interactions were observed between heparin and amyloid-formed light chains.
• Molecular modeling suggested heparin interacts with a conserved surface on the light chain dimer.

Conclusions:

• GAGs, particularly heparin, bind to amyloid-associated light chains.
• This interaction may offer a novel therapeutic strategy to block amyloid formation.
• A hexasaccharide structure was modeled as a potential antagonist for amyloid aggregation.